Document is current
Any future updates will be listed below
-
Authors
Petriti, Bledi
Rabiolo, Alessandro http://orcid.org/0000-0002-7772-5929
Chau, Kai-Yin
Williams, Pete A. http://orcid.org/0000-0001-6194-8397
Montesano, Giovanni http://orcid.org/0000-0002-9148-2804
Lascaratos, Gerassimos http://orcid.org/0000-0001-5936-1431
Garway-Heath, David F. http://orcid.org/0000-0003-2907-6992
-
Funding
Funding for this research was provided by:
Santen (3830272, 3830272)
Fight for Sight UK (5023/5024, 5023/5024, 5023/5024)
International Glaucoma Association (UKEGS 2017/8, UKEGS 2017/8, UKEGS 2017/8)
Rosetrees Trust (Seedcorn2020\100118, Seedcorn2020\100118)
- License Information
-
More Information
Article History
Received: 13 September 2023
Accepted: 14 May 2024
First Online: 17 June 2024
Competing interests
: D.G.-H. received consultation fees from Abbvie, Janssen, Omikron, Roche, Santen and Viatris. G.M. received consultation fees from Alcon and Omikron. G.L. has research funding from Aerie, Abbvie and other remuneration received by Glaukos and Rayner. P.A.W. is an inventor on an awarded US patent held by The Jackson Laboratory for NAM treatment in glaucoma (Treatment and prevention of ocular neurodegenerative disorder, US11389439B2).
